Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaBen add-on to clozapine for residual symptoms in refractory schizophrenia
2017-001170-42Phase 2Active
- Sponsor
- SyneuRx
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium benzoate in schizophrenia (3 arms), sponsored by SyneuRx. Primary endpoint: Mean change from baseline in PANSS total score. Started Oct 2018; status: active.
02
Drugs
sodium benzoate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-001170-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001170-42.